Healthcare -
Medical - Pharmaceuticals - NASDAQ - US
$ 0.009
0 %
$ 4.48 M
Market Cap
None
P/E
1. INTRINSIC VALUE
Balance Sheet
CannBioRx Life Sciences Corp.
| Current Assets | 3.64 M |
| Cash & Short-Term Investments | 1.98 M |
| Receivables | 0 |
| Other Current Assets | 1.66 M |
| Non-Current Assets | 1.62 M |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 1.62 M |
| Current Liabilities | 5.06 M |
| Accounts Payable | 1.89 M |
| Short-Term Debt | 1.03 M |
| Other Current Liabilities | 2.14 M |
| Non-Current Liabilities | 325 K |
| Long-Term Debt | 19.9 K |
| Other Non-Current Liabilities | 305 K |
EFFICIENCY
Earnings Waterfall
CannBioRx Life Sciences Corp.
| Revenue | 0 |
| Cost Of Revenue | 106 K |
| Gross Profit | -106 K |
| Operating Expenses | 13.5 M |
| Operating Income | -13.5 M |
| Other Expenses | 6.46 M |
| Net Income | -19.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CannBioRx Life Sciences Corp.
| Net Income | -19.9 M |
| Depreciation & Amortization | 106 K |
| Capital Expenditures | 3 |
| Stock-Based Compensation | 2.28 M |
| Change in Working Capital | -14.1 K |
| Others | 8.69 M |
| Free Cash Flow | -10.9 M |
Wall Street Analysts Price Targets
CannBioRx Life Sciences Corp.
ATNFW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ATNFW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CannBioRx Life Sciences Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Dec 15, 2023
|
Sell 4.7 K
USD
|
Feldmann Marc
Director
|
- 25000
|
0.188 USD |
|
1 year ago
Dec 15, 2023
|
Bought
4.7 K USD
|
Woody James N.
Chief Executive Officer
|
+ 25000
|
0.188 USD |
|
1 year ago
Jun 01, 2023
|
Bought
22.1 K USD
|
STEINMAN LAWRENCE
Director
|
+ 18000
|
1.226 USD |
|
1 year ago
May 31, 2023
|
Bought
11.5 K USD
|
McGovern Jr. Donald A.
Director
|
+ 10000
|
1.147 USD |
|
1 year ago
May 19, 2023
|
Bought
5.8 K USD
|
McGovern Jr. Donald A.
Director
|
+ 5000
|
1.16 USD |
|
1 year ago
May 18, 2023
|
Bought
10.5 K USD
|
McGovern Jr. Donald A.
Director
|
+ 10000
|
1.05 USD |
|
1 year ago
May 18, 2023
|
Bought
7.51 K USD
|
Marrone Pamela G
Director
|
+ 7082.019
|
1.06 USD |
|
1 year ago
May 18, 2023
|
Bought
5.21 K USD
|
Pamir Ozan
CFO
|
+ 5162.077
|
1.01 USD |
|
1 year ago
May 18, 2023
|
Bought
41.2 K USD
|
Woody James N.
Chief Executive Officer
|
+ 40000
|
1.03 USD |
7. News
8. Profile
Summary
CannBioRx Life Sciences Corp. ATNFW
COUNTRY
US
INDUSTRY
Medical - Pharmaceuticals
MARKET CAP
$ 4.48 M
Dividend Yield
0.00%
Description
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Contact
Building 4, Palo Alto, 94306
http://www.180lifesciences.com
IPO
Date
None
Employees
4
Officers
Dr. Lawrence Steinman BA, M.D., Ph.D.
Co-Founder & Director
Prof. Jagdeep Nanchahal M.D., Ph.D.
Co-Founder & Chairman of Clinical Advisory Board
Sir Marc Feldmann Ph.D.
Co-Founder
Mr. Jason Assad
Director of IR